Assessing the impact of drug use on hospital costs

Health Services Research

Volumn 44, Issue 1, 2009, Pages 128-144

  Stuart, Bruce C ^a   Doshi, Jalpa A ^b,c   Terza, Joseph V ^d  

^a UNIVERSITY OF MARYLAND   (United States)

^b Center for Evidence Based Practice

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Drug cost offsets; Hospital spending; Indication bias; Instrumental variables; Medicare

Indexed keywords

AGED; AGED, 80 AND OVER; DRUG PRESCRIPTIONS; FEMALE; HOSPITAL COSTS; HUMANS; INSURANCE COVERAGE; MALE; MEDICARE; MODELS, STATISTICAL; RISK ADJUSTMENT; UNITED STATES;

EID: 58349110979     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/j.1475-6773.2008.00897.x     Document Type: Article

References (41)

1. Avorn J. 2004. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York : Alfred Knopf.
2. Balkrishnan, R., W. G. Byerly, F. T. Camacho, A. Shrestha R. T. Anderson. 2001 Effect of Prescription Benefit Charges on Medical Care Utilization in a Medicare HMO Population American Journal of Managed Care 7 : 1093 100.
3. Briesacher, B., B. Stuart, J. Doshi M. Wrobel. 2005 Medicare Beneficiaries and the Impact of Gaining Prescription Drug Coverage on Inpatient and Physician Spending Health Services Research 40 (5, part 1) : 1279 96.
4. Choudhry, N., A. Patrick, E. Antiman, J. Avorn W. Shrank. 2008 Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare Beneficiaries Circulation 117 (10) : 1261 8.
5. Christian-Herman J., M. Emons D. George. 2004 Effects of Generic-Only Drug Coverage in a Medicare HMO Health Affairs (Web Exclusives) : W455 68.
6. Culler, S. D., M. L. Parchman M. Przybylski. 1998 Factors Related to Potentially Preventable Hospitalizations among the Elderly Medical Care 36 (6) : 804 17.
7. Doshi, J., H. Glick D. Polsky. 2006 Analysis of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials Value in Health 9 (5) : 334 40.
8. Duggan, M. 2004 Do New Prescription Drugs Pay for Themselves? Journal of Health Economics 24 : 1 31.
9. Fairman, K. A., B. R. Motheral R. R. Henderson. 2003 Retrospective, Long-Term Follow-Up Study of the Effect of a Three-Tier Prescription Drug Copayment System on Pharmocological and Medical Utilization and Costs Clinical Therapeutics 25 : 3147 66.
10. Fischer, M. J. Avorn. 2004 Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less? Journal of the American Medical Association 291 (15) : 1850 6.
11. Gibson, T. B., R. J. Ozminkowski R. Z. Goetzel. 2005 The Effects of Prescription Drug Cost Sharing: A Review of the Evidence American Journal of Managed Care 11 (11) : 730 40.
12. Heffler, S., S. Smith, S. Keehan, C. Borger, M. Clemens C. Truffer. 2005 U.S. Health Spending Projections for 2004-2114 Health Affairs 24 (suppl) : W5 W74 (February).
13. Johnson, R. E., M. J. Goodman, M. C. Hornbrook M. B. Eldridge. 1997 The Effect of Increased Prescription Drug Cost-Sharing on Medical Care Utilization and Expenses of Elderly Health Maintenance Organization Members Medical Care 35 : 1119 31.
14. Lichtenberg, F. R. 1996 Do (More and Better) Drugs Keep People out of Hospitals? American Economic Review 86 (2) : 384 8.
15. Lichtenberg, F. R. 2001 Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 MEPS Health Affairs 20 (5) : 241 51.
16. Lichtenberg, F. R. 2002. "Benefits and Costs of Newer Drugs: An Update." Working Paper 8996. National Bureau of Economic Research.
17. Motheral, B. M. K. A. Fairman. 2001 Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization Medical Care 39 (12) : 1293 304.
18. Mullahy, J. 1998 Much Ado About Two: Reconsidering Retransformation and the Two-Part Model in Health Econometrics Journal of Health Economics 17 : 247 81.
19. Pauly, M. 2004 Medicare Drug Coverage and Moral Hazard Health Affairs 23 : 113 22.
20. Pilote, L., C. Beck, H. Richard M. J. Eisenberg. 2002 The Effects of Cost-Sharing on Essential Drug Prescriptions, Utilization of Medical Care and Outcomes after Acute Myocardial Infarction in Elderly Patients Canadian Medical Association Journal 167 : 246 52.
21. Pope, G. J. Kautter, R. Ellis, A. Ash J. Aranian, L. Iezzoni, M. Ingber J. Levey J. Robst. 2004 Risk Adjustment of the Medicare Capitation Payments Using the CMS-HCC Model Health Care Financing Review 25 (4) : 119 41.
22. Ramsey, S., R. Willke, A. Briggs, R. Brown, M. Buxton, A. Chawla J. Cook, H. Glick, L. Bengt, D. Pettiti S. Reed. 2005 Good Research Practice for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report Value in Health 8 (5) : 521 33.
23. Rice, T. K. Y. Matsuoka. 2004 The Impact of Cost-Sharing on Appropriate Utilization and Health Status: A Review of the Literature on Seniors Medical Care Research and Review 61 (4) : 415 52.
24. Rosen, A., M. Hamel, M. Weinstein, D. Cutler, A. Fendrick S. Vijan. 2005 Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes Annals of Internal Medicine 143 : 89 99.
25. Shea, D. G. J. V. Terza, B. C. Stuart B. Briesacher. 2007 Estimating the Effects of Prescription Drug Coverage for Medicare Beneficiaries Health Services Research 43 : 933 49.
26. Soumerai, S. B., D. Ross-Degnan, J. Avon, I. T. McLaughlin I. Choodnovskiy. 1991 Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes New England Journal of Medicine 325 (15) : 1072 7.
27. Soumerai, S. B., T. McLaughlin, D. Ross-Degnan, C. Casteris P. Bollini. 1994 Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia New England Journal of Medicine 331 (10) : 650 5.
28. Stuart, B., B. Briesacher, J. Doshi, M. Wrobel F. Baysac. 2007a Will Part D Produce Savings in Part A and Part B? The Impact of Prescription Drug Coverage on Medicare Program Expenditures Inquiry 44 (2) : 146 56.
29. Stuart, B., B. Briesacher, D. Shea, B. Cooper, F. Baysac R. Limcangco. 2005b Riding the Rollercoaster: The Ups and Downs in Out-of-Pocket Spending under the New Medicare Benefit Health Affairs 24 (4) : 1022 31.
30. Stuart, B., J. Doshi, B. Briesacher, M. Wrobel F. Baysac. 2004 Impact of Prescription Coverage on Hospital and Physician Costs: A Case Study of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Clinical Therapeutics 26 (10) : 1688 99.
31. Stuart, B., L. Simoni-Wastila, F. Baysac, T. Shaffer D. Shea. 2006 Coverage and Use of Prescription Drugs in Nursing Homes: Implications for the Medicare Modernization Act Medical Care 44 (3) : 243 9.
32. Stuart, B., L. Simoni-Wastila D. Chauncey. 2005a Assessing the Impact of Coverage Gaps in the Medicare Part D Drug Benefit Health Affairs 24 (suppl 1, Web Exclusives) : W5-167 79.
33. Stuart, B., L. Simoni-Wastila, I. Zuckerman, J. Doshi, D. Shea, T. Shaffer L. Zhao. 2007b. Chartbook of Medication Use by Aged and Disabled Medicare Beneficiaries across the Spectrum of Morbidity. Baltimore : The Peter Lamy Center on Drug Therapy and Aging.
34. Tamblyn, R., R. Laprise J. Hanley, M. Abrahamowicz, S. Scott, N. Mato J. Hurley, R. Grad, E. Latimer, R. Perreault, P. McLeod, A. Huang, P. Lavochettle L. Mallet. 2001 Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons Journal of the American Medical Association 285 (4) : 421 9.
35. Terza, J., W. D. Bradford C. E. Dismuke. 2008 The Use of Linear Instrumental Variables Methods in Health Services Research and Health Economics: A Cautionary Note Health Services Research 43 : 1102 20.
36. Terza, J., A. Basu P. Rathouz. 2008 Two-Stage Residual Inclusion Estimation: Addressing Endogeneity in Health Econometric Modeling Journal of Health Economics 27 : 531 43.
37. Terza, J. V. 2006 Estimation of Policy Effects Using Parametric Nonlinear Models: A Contextual Critique of the Generalized Method of Moments Health Services and Outcomes Research Methodology 6 : 177 98.
38. U.S. Congressional Budget Office. 2002. Issues in Designing a Prescription Drug Benefit for Medicare. Washington, DC : U.S. Government Printing Office.
39. Wertheimer, A., R. Levy T. O'Connor. 2001 Too Many Drugs? The Clinical and Economic Value of Incremental Innovations Investing in Health: The Social and Economic Benefits of Health Care Innovation 14 : 77 118.
40. White, H. 1994. Estimation, Inference and Specification Analysis. Cambridge : Cambridge University Press.
41. Wrobel, M., J. Doshi, B. Stuart B. Briesacher. 2003 Predictability of Drug Expenditures for Medicare Beneficiaries Health Care Financing Review 25 (2) : 37 46.